XML 54 R40.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Acquisitions - Narrative (Details) $ in Thousands |  |  |  |  |  |  |  |  |  |  |  | 3 Months Ended | 5 Months Ended | 6 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
May 23, 2018 USD ($) | May 18, 2018 USD ($) | Apr. 06, 2018 USD ($) | Feb. 14, 2018 USD ($) | Oct. 02, 2017 USD ($) | Aug. 04, 2017 USD ($) | Jul. 03, 2017 USD ($) | May 01, 2017 USD ($) | Jan. 31, 2017 USD ($) patents | Jul. 06, 2016 USD ($) | Feb. 04, 2016 USD ($) | Jun. 30, 2018 USD ($) | Jun. 30, 2018 USD ($) | Jun. 30, 2018 USD ($) | Jun. 30, 2018 USD ($) | Jun. 30, 2017 USD ($) | Dec. 31, 2017 USD ($) | Dec. 31, 2016 USD ($)
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to acquire intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,755 | $ 1,082 |  |
Loan for long-term agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10,500 | 0 |  |
QX Medical, LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to acquire intangible assets |  | $ 750 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
NinePoint |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net sales related to acquisition |  |  |  |  |  |  |  |  |  |  |  | $ 1,100 |  |  |  |  |  |
Option to purchase outstanding equity, up to |  |  | 100.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration received, option to purchase remaining equity |  |  | $ 10,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Loan for long-term agreement |  |  | $ 10,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest rate on loan |  |  | 9.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Distribution agreements | QX Medical, LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  | 10 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
DirectACCESS Medical, LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price | $ 7,300 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life | 9 years 11 months |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
DirectACCESS Medical, LLC | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life | 10 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
DirectACCESS Medical, LLC | Trademarks |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life | 10 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
DirectACCESS Medical, LLC | Customer Lists |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Becton, Dickinson and Company |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  | $ 100,300 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net sales related to acquisition |  |  |  |  |  |  |  |  |  |  |  |  | $ 12,200 |  | 18,500 |  |  |
Acquisition-related costs |  |  |  |  |  |  |  |  |  |  |  |  | 41 |  | 1,800 |  |  |
Weighted average useful life |  |  |  | 8 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Working capital adjustment |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 158 |  |  |  |
Becton, Dickinson and Company | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  | 8 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Becton, Dickinson and Company | Trademarks |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  | 9 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Becton, Dickinson and Company | Customer Lists |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  | 7 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
ITL Healthcare Pty Ltd |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  |  | $ 11,300 |  |  |  |  |  |  |  |  |  |  |  |  |
Net sales related to acquisition |  |  |  |  |  |  |  |  |  |  |  |  | 2,000 |  | 4,200 |  |  |
ITL Healthcare Pty Ltd | Customer Lists |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  | 7 years |  |  |  |  |  |  |  |  |  |  |  |  |
Laurane Medical S.A.S. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  |  |  | $ 16,500 |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  |  | 11 years 11 months |  |  |  |  |  |  |  |  |  |  |  |
Contingent liability |  |  |  |  |  | $ 5,500 |  |  |  |  |  |  |  |  |  |  |  |
Laurane Medical S.A.S. | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  | 12 years |  |  |  |  |  |  |  |  |  |  |  |
Laurane Medical S.A.S. | Customer Lists |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  | 1 year |  |  |  |  |  |  |  |  |  |  |  |
Osseon LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  |  |  |  | $ 6,800 |  |  |  |  |  |  |  |  |  |  |
Net sales related to acquisition |  |  |  |  |  |  |  |  |  |  |  |  | 588 |  | 1,100 |  |  |
Weighted average useful life |  |  |  |  |  |  | 8 years 11 months 15 days |  |  |  |  |  |  |  |  |  |  |
Osseon LLC | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  | 9 years |  |  |  |  |  |  |  |  |  |  |
Osseon LLC | Customer Lists |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  | 8 years |  |  |  |  |  |  |  |  |  |  |
Vascular Access Technologies, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  |  |  |  |  | $ 5,000 |  |  |  |  |  |  |  |  |  |
Contingent liability |  |  |  |  |  |  |  | $ 4,900 |  |  |  |  |  |  |  |  |  |
Vascular Access Technologies, Inc. | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  |  | 15 years |  |  |  |  |  |  |  |  |  |
Argon Medical Devices, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  |  |  |  |  |  | $ 10,900 |  |  |  |  |  |  | $ 10,100 |  |
Net sales related to acquisition |  |  |  |  |  |  |  |  |  |  |  |  | 11,200 |  | 23,700 |  |  |
Weighted average useful life |  |  |  |  |  |  |  |  | 5 years 11 months 15 days |  |  |  |  |  |  |  |  |
Working capital adjustment |  |  |  |  |  |  |  |  | $ (797) |  |  |  |  |  |  |  |  |
Argon Medical Devices, Inc. | Cardiovascular Segment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition-related costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,600 |
Argon Medical Devices, Inc. | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  |  |  | 7 years |  |  |  |  |  |  |  |  |
Argon Medical Devices, Inc. | Trademarks |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  |  |  | 5 years |  |  |  |  |  |  |  |  |
Argon Medical Devices, Inc. | Customer Lists |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  |  |  | 5 years |  |  |  |  |  |  |  |  |
Catheter Connections, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  |  |  |  |  |  | $ 38,000 |  |  |  |  |  |  |  |  |
Net sales related to acquisition |  |  |  |  |  |  |  |  |  |  |  |  | 3,100 |  | 6,300 |  |  |
Weighted average useful life |  |  |  |  |  |  |  |  | 11 years 8 months |  |  |  |  |  |  |  |  |
Number of patents acquired | patents |  |  |  |  |  |  |  |  | 40 |  |  |  |  |  |  |  |  |
Catheter Connections, Inc. | Cardiovascular Segment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition-related costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 482 |
Catheter Connections, Inc. | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  |  |  | 12 years |  |  |  |  |  |  |  |  |
Catheter Connections, Inc. | Trademarks |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  |  |  | 10 years |  |  |  |  |  |  |  |  |
Catheter Connections, Inc. | Customer Lists |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  |  |  | 8 years |  |  |  |  |  |  |  |  |
DFINE, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  |  |  |  |  |  |  | $ 97,500 |  |  |  |  |  |  |  |
Net sales related to acquisition |  |  |  |  |  |  |  |  |  |  |  |  | 7,200 |  | 14,500 |  |  |
Weighted average useful life |  |  |  |  |  |  |  |  |  | 14 years 10 months |  |  |  |  |  |  |  |
Consideration paid related to net working capital adjustment |  |  |  |  |  |  |  |  |  | $ 578 |  |  |  |  |  |  |  |
Trade receivables acquired, gross |  |  |  |  |  |  |  |  |  | 4,300 |  |  |  |  |  |  |  |
Trade receivables, expected to be uncollectible |  |  |  |  |  |  |  |  |  | $ 224 |  |  |  |  |  |  |  |
DFINE, Inc. | Cardiovascular Segment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition-related costs |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,600
DFINE, Inc. | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  |  |  |  | 15 years |  |  |  |  |  |  |  |
DFINE, Inc. | Trademarks |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  |  |  |  | 15 years |  |  |  |  |  |  |  |
DFINE, Inc. | Customer Lists |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  |  |  |  | 9 years |  |  |  |  |  |  |  |
HeRO®Graft |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  |  |  |  |  |  |  |  | $ 18,500 |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  |  |  |  |  |  |  | 9 years 9 months 25 days |  |  |  |  |  |  |
Income since acquisition date |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,200 |  | $ 4,200 |  |  |
HeRO®Graft | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  |  |  |  |  | 10 years |  |  |  |  |  |  |
HeRO®Graft | Trademarks |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  |  |  |  |  | 5 years 6 months |  |  |  |  |  |  |
HeRO®Graft | Customer Lists |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  |  |  |  |  | 12 years |  |  |  |  |  |  |

X
- Definition Business Acquisition, Consideration Received, Option to Purchase Remaining Equity + References No definition available. + Details
Name: | mmsi_BusinessAcquisitionConsiderationReceivedOptiontoPurchaseRemainingEquity
Namespace Prefix: | mmsi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Acquisition, Option To Acquire Percentage of Voting Interests + References No definition available. + Details
Name: | mmsi_BusinessAcquisitionOptionToAcquirePercentageofVotingInterests
Namespace Prefix: | mmsi_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Trade Receivables, Allowance for Doubtful Accounts + References No definition available. + Details
Name: | mmsi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsTradeReceivablesAllowanceforDoubtfulAccounts
Namespace Prefix: | mmsi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Trade Receivables Gross + References No definition available. + Details
Name: | mmsi_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsTradeReceivablesGross
Namespace Prefix: | mmsi_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Notes Receivable, Interest Rate, Stated Percentage + References No definition available. + Details
Name: | mmsi_NotesReceivableInterestRateStatedPercentage
Namespace Prefix: | mmsi_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of Patents Acquired + References No definition available. + Details
Name: | mmsi_NumberofPatentsAcquired
Namespace Prefix: | mmsi_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -URI http://asc.fasb.org/extlink&oid=84229725&loc=d3e1043-128460 + Details
Name: | us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of tangible or intangible assets, including a business or subsidiary of the acquirer transferred by the entity to the former owners of the acquiree. Excludes cash. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferredOther1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 4A -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=84161108&loc=SL65897772-128472 + Details
Name: | us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireNotesReceivable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=mmsi_QXMedicalLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mmsi_NinePointMedicalInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mmsi_DirectACCESSMedicalLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerListsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mmsi_BectonDickinsonandCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mmsi_ITLHealthcarePtyLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mmsi_LauraneMedicalS.A.S.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mmsi_OsseonLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mmsi_VascularAccessTechnologiesInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mmsi_ArgonMedicalDevicesInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mmsi_CardiovascularSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mmsi_CatheterConnectionsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mmsi_DFINEInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mmsi_HeROGraftMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |